PCSA
Processa Pharmaceuticals, Inc. NASDAQ Listed Mar 7, 2014$1.86
-1.59%
vs $1.89
Mkt Cap $2.4M
52w Low $1.85
0.1% of range
52w High $11.97
50d MA $2.56
200d MA $4.23
P/E (TTM)
—
EV/EBITDA
—
P/B
0.4x
Debt/Equity
0.0x
ROE
-243.2%
P/FCF
-0.2x
RSI (14)
29.90
ATR (14)
$0.28
Beta
0.89
50d MA
$2.56
200d MA
$4.23
Avg Volume
72.4K
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
7380 Coca Cola Drive · Hanover, MD 21076 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -1.50 | -18.50 | -1133.3% | 2.33 | -1.7% | -0.4% | +1.3% | -0.9% | -1.3% | -2.6% | — |
| Nov 6, 2025 | AMC | -2.00 | -1.75 | +12.5% | 7.90 | -5.1% | -3.2% | +12.8% | -8.5% | +3.2% | -10.4% | — |
| Aug 7, 2025 | AMC | -0.23 | -0.25 | -8.7% | 5.78 | -0.5% | +0.3% | -3.8% | -1.1% | +3.3% | -3.3% | — |
| May 8, 2025 | AMC | -0.77 | -0.30 | +61.0% | 6.85 | -1.9% | -12.7% | -0.2% | -4.0% | +2.1% | +5.6% | — |
| Mar 20, 2025 | AMC | -0.92 | -0.74 | +19.6% | 10.63 | +1.7% | +1.1% | +2.0% | -8.8% | -2.1% | -0.4% | — |
| Oct 30, 2024 | AMC | -1.00 | -1.03 | -3.0% | 33.25 | +0.0% | -12.8% | -0.9% | -3.5% | -0.9% | +1.8% | — |
| Aug 13, 2024 | AMC | -0.98 | -1.01 | -3.1% | 34.00 | +0.7% | -0.7% | -3.0% | +10.7% | +4.8% | -0.7% | — |
| May 10, 2024 | AMC | -1.18 | -1.11 | +5.9% | 52.25 | +4.8% | +6.2% | -1.8% | -7.3% | -1.0% | -2.0% | — |
| Mar 29, 2024 | AMC | -1.60 | -0.24 | +85.0% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.10 | -1.60 | -1500.0% | 189.00 | +4.5% | +8.7% | -4.1% | +5.6% | +3.4% | -1.2% | — |
| Aug 10, 2023 | AMC | -3.00 | -2.00 | +33.3% | 185.50 | +0.0% | +7.8% | -1.0% | -2.0% | +0.3% | +0.0% | — |
| May 15, 2023 | AMC | -5.60 | -3.60 | +35.7% | 329.50 | -1.4% | -8.2% | +9.1% | +0.0% | +0.0% | +2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.72 | $4.72 | +0.0% | -0.4% | -0.2% | -9.6% | +1.4% | +6.0% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.91 | $5.03 | +2.4% | +4.5% | -2.5% | -5.8% | +3.4% | -0.4% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.25 | $25.25 | +0.0% | +1.0% | +1.0% | +21.4% | +6.4% | -5.3% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.00 | $36.75 | -3.3% | -0.7% | +1.3% | -3.3% | -2.0% | +0.0% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.25 | $35.25 | -2.8% | +4.8% | -0.7% | +1.3% | -3.3% | -2.0% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.50 | $53.00 | +1.0% | -0.5% | -8.1% | -7.3% | +4.5% | -3.8% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.00 | $44.25 | -1.7% | -11.1% | +3.1% | +6.1% | +5.7% | -1.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.25 | $54.75 | +4.8% | +6.2% | -1.8% | -7.3% | -1.0% | -2.0% |
| Mar 6 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $57.00 | $61.25 | +7.5% | +1.8% | -0.4% | -1.7% | +0.4% | -0.4% |
| Nov 17 | Maxim Group | Downgrade | Buy → Hold | — | $208.00 | $217.50 | +4.6% | +3.4% | -1.2% | -6.4% | +9.3% | +8.0% |
| Apr 3 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $250.00 | $265.00 | +6.0% | -3.0% | +1.0% | -4.3% | +0.2% | +6.4% |
| Apr 2 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jan 11 | Maxim Group | Maintains | Buy → Buy | — | $605.00 | $609.00 | +0.7% | +2.5% | +4.8% | -3.8% | -0.8% | -1.6% |
| Apr 19 | Maxim Group | Maintains | Buy → Buy | — | $1435.00 | $1610.00 | +12.2% | +9.1% | -2.2% | -3.5% | -10.6% | +6.4% |
| Aug 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $3000.00 | $3270.00 | +9.0% | -0.8% | -3.4% | +7.8% | -0.3% | +0.0% |
| Aug 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $2990.00 | $3025.00 | +1.2% | +0.3% | -0.8% | -3.4% | +7.8% | -0.3% |
| Oct 28 | Craig-Hallum | Maintains | Buy → Buy | — | $2085.00 | $2115.00 | +1.4% | -0.2% | +1.0% | -2.1% | +1.2% | +0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Guy Wendy | Chief Administrative Officer | Buy | 2,118 | $2.22 | $5K | 11,958 | +2.87% | -4.46% |
| Jun 15, 2026 | Lin Patrick | Chief Business - Strategy Off | Buy | 1,831 | $2.22 | $4K | 11,007 | +2.87% | -4.46% |
| Jun 15, 2026 | Ng George K | Chief Executive Officer | Buy | 2,465 | $2.22 | $5K | 12,435 | +2.87% | -4.46% |
| Jun 15, 2026 | SKIBSTED RUSSELL | Chief Financial Officer | Buy | 2,654 | $2.22 | $6K | 13,412 | +2.87% | -4.46% |
| Jun 15, 2026 | Young David | Pres. Research & Development | Buy | 2,067 | $2.22 | $5K | 19,198 | +2.87% | -4.46% |
| May 29, 2026 | Guy Wendy | Chief Administrative Officer | Buy | 1,829 | $2.57 | $5K | 9,840 | +15.41% | -3.97% |
| May 29, 2026 | Lin Patrick | Chief Business - Strategy Off | Buy | 1,582 | $2.57 | $4K | 9,176 | +15.41% | -3.97% |
| May 29, 2026 | Ng George K | Chief Executive Officer | Buy | 2,129 | $2.57 | $5K | 9,970 | +15.41% | -3.97% |
| May 29, 2026 | SKIBSTED RUSSELL | Chief Financial Officer | Buy | 2,292 | $2.57 | $6K | 10,758 | +15.41% | -3.97% |
| May 29, 2026 | Young David | Pres. Research & Development | Buy | 1,786 | $2.57 | $5K | 17,131 | +15.41% | -3.97% |
| May 15, 2026 | SKIBSTED RUSSELL | Chief Financial Officer | Buy | 1,984 | $2.97 | $6K | 8,466 | +0.00% | -4.40% |
| May 15, 2026 | Young David | Pres. Research & Development | Buy | 1,545 | $2.97 | $5K | 15,345 | +0.00% | -4.40% |
| May 15, 2026 | Lin Patrick | Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4K | 7,594 | +0.00% | -4.40% |
| May 15, 2026 | Guy Wendy | Chief Administrative Officer | Buy | 1,583 | $2.97 | $5K | 8,011 | +0.00% | -4.40% |
| May 15, 2026 | Ng George K | Chief Executive Officer | Buy | 1,843 | $2.97 | $5K | 7,841 | +0.00% | -4.40% |
| Apr 30, 2026 | Bigora Sian | Chief Development Officer | Buy | 1,971 | $2.71 | $5K | 7,481 | +0.00% | -4.40% |
| Apr 30, 2026 | Young David | Pres. Research & Development | Buy | 1,706 | $2.69 | $5K | 13,813 | +5.10% | -4.88% |
| Apr 30, 2026 | Lin Patrick | Chief Business - Strategy Off | Buy | 1,511 | $2.69 | $4K | 6,236 | +5.10% | -4.88% |
| Apr 30, 2026 | Ng George K | Chief Executive Officer | Buy | 2,034 | $2.69 | $5K | 6,013 | +5.10% | -4.88% |
| Apr 30, 2026 | Guy Wendy | Chief Administrative Officer | Buy | 1,748 | $2.69 | $5K | 6,441 | +5.10% | -4.88% |
| Apr 30, 2026 | Bigora Sian | Chief Development Officer | Buy | 1,986 | $2.69 | $5K | 7,496 | +5.10% | -4.88% |
| Apr 30, 2026 | SKIBSTED RUSSELL | Chief Financial Officer | Buy | 2,190 | $2.69 | $6K | 6,498 | +5.10% | -4.88% |
| Apr 15, 2026 | Ng George K | Chief Executive Officer | Buy | 1,843 | $2.97 | $5K | 3,979 | +0.00% | -4.40% |
| Apr 15, 2026 | Ng George K | Chief Executive Officer | Buy | 1,843 | $2.97 | $5K | 3,979 | -5.56% | +4.36% |
| Mar 31, 2026 | Ng George K | Chief Executive Officer | Buy | 2,136 | $2.54 | $5K | 2,136 | -5.56% | +4.36% |
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Two healthcare/biotech companies added a blockchain and health informatics expert to leadership, signaling strategic focus on data integrity and emerging tech applications—potentially improving clinical trial credibility and operational efficiency.
Mar 20
8-K · 1.02
!! High
Processa Pharmaceuticals, Inc. Common -- 8-K 1.02: Material Agreement Terminated
Processa Pharmaceuticals' licensing agreement with Intact Therapeutics for PCS12852 expired without a definitive deal, eliminating a planned collaboration and potentially affecting the drug's development timeline and partnership prospects.
Feb 19
Institutional (13F) — Top 6
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Connective Capital Management, Llc | 70,736 | $179K | New | Mar 2026 |
| 2 | Stonepine Capital Management, Llc | 55,000 | $139K | Added | Mar 2026 |
| 3 | Jane Street Group, Llc | 30,190 | $87K | New | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 12,729 | $32K | New | Mar 2026 |
| 5 | Ubs Group Ag | 2,531 | $6K | Reduced | Mar 2026 |
| 6 | Wells Fargo & Company/mn | 6 | $15 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 14,665 | $32K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 2,088 | $5K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 969 | $2K | Feb 2026 |
Valuation
Market Cap
$2.4M
Enterprise Value
-$3.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.44x
P/S
—
P/FCF
-0.21x
EV/EBITDA
—
Shares Out
1.3M
Financials (TTM)
Revenue
$0
Net Income
-$14.1M
EBITDA
-$14.1M
Free Cash Flow
-$11.4M
Op Cash Flow
-$11.4M
EPS Basic
$-10.36
EPS Diluted
$-10.66
EPS Forward
$-6.00
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.8M
Total Liab.
$2.2M
Total Equity
$5.6M
Cash
$5.5M
LT Debt
$0
Book Value/Sh
$4.26
Debt/Equity
0.00x
Current Ratio
2.54
Quick Ratio
2.54
Returns & Growth
ROE
-243.2%
ROA
-173.6%
ROIC
-250.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+89.3%
Price Returns
2W
-16.6%
1M
-5.2%
3M
+18.0%
6M
-60.5%
12M
-65.0%
Technicals
52W High
$11.97
52W Low
$1.85
50d MA
$2.56
200d MA
$4.23
RSI (14)
29.90
ATR (14)
$0.28
Beta
0.89
Avg Volume
72K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$225.00
High
$225.00
Low
$225.00
Median
$225.00
Data updated apr 26, 2026 6:59pm
· Source: financialmodelingprep.com